SCHEMBL978291

SCHEMBL978291

O=C(O)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.71
ALDH1A1 P00352 5/20 0.69
CYP2C9 P11712 2/20 0.66
CYP1A2 P05177 1/20 0.66
POLB P06746 2/20 0.63
NPSR1 Q6W5P4 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
MAPK1 P28482 1/20 0.60
RAB9A P51151 1/20 0.57
MAPT P10636 4/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
HTT P42858 3/20 0.56
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10754121 0.98 KDM4E (0.69) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL7032770 0.93 KDM4E (0.63) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL10470177 0.91 ALDH1A1 (0.63) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL10469508 0.91 ALDH1A1 (0.63) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL3876532 0.89 CYP1A2 (0.61) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL10469100 0.89 ALDH1A1 (0.60) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL7694742 0.89 KDM4E (0.73) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL7697964 0.88 KDM4E (0.68) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL10470167 0.87 ALDH1A1 (0.67) KDM4EALDH1A1CYP2C9CYP1A2POLB
SCHEMBL10470173 0.87 FOLH1 (0.58) KDM4EALDH1A1CYP2C9CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118541147-B Novel compound CX-1 and therapeutic use thereof in inflammatory diseases and tumors 中国医学科学院基础医学研究所 2025-04-11 CN claimed
CN-118541147-A Novel compound CX-1 and therapeutic use thereof in inflammatory diseases and tumors 中国医学科学院基础医学研究所 2024-08-23 CN claimed
EP-1907360-B1 IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE GLADE ORGANICS PRIVATE LTD (IN) 2011-03-30 EP claimed
US-20100184990-A1 Process for the Manufacture of Flecainide GLADE ORGANICS PRIVATE LIMITED (IN) 2010-07-22 US claimed
US-20100056794-A1 PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYL-METHYL)-BENZAMIDE AND SALTS THEREOF GRINDEKS A JOINT STOCK COMPANY (LV) 2010-03-04 US claimed
EP-1907360-A4 IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE GLADE ORGANICS PRIVATE LTD (IN) 2009-04-01 EP claimed
EP-1918280-A1 Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide and salts thereof "Joint Stock Company Grindeks" (LV) 2008-05-07 EP claimed
EP-1907360-A1 IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE Glade Organics Private Limited (IN) 2008-04-09 EP claimed
US-7196197-B2 Process for the preparation of Flecainide, its pharmaceutically acceptable salts and important intermediates thereof APOTEX PHARMACHEM INC. 2007-03-27 US claimed
WO-2007003982-A1 IMPROVED PROCESS FOR THE MANUFACTURE OF FLECAINIDE GLADE ORGANICS PRIVATE LIMITED (IN) 2007-01-11 WO claimed
EP-1309538-A2 METHOD FOR THE PRODUCTION OF TRIFLUOROETHOXY-SUBSTITUTED BENZOIC ACIDS MERCK PATENT GmbH (DE) 2003-05-14 EP claimed
US-6538138-B1 Reacting 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid or salt with haloacetonitrile in base presence; amidation, salt formation FINETECH LTD. (IL) 2003-03-25 US claimed
US-20020133013-A1 Process for making cyanomethyl ester precursors of flecainide FINETECH LTD. 2002-09-19 US claimed
WO-2002066413-A1 FLECAINIDE SYNTHESIS NARCHEM CORPORATION (US) 2002-08-29 WO claimed
WO-2001090062-A2 METHOD FOR THE PRODUCTION OF TRIFLUOROETHOXY-SUBSTITUTED BENZOIC ACIDS MERCK PATENT GMBH (DE) 2001-11-29 WO claimed
US-6316627-B1 REACTING A HALOBENZOIC ACID OR ITS SALT WITH WITH 2,2,2-TRIFLUOROETHANOL IN THE PRESENCE OF A STRONG BASE AND COPPER OR A COPPER COMPOUND OR ALLOY, IF DESIRED FOLLOWED BY ACIDIFICATION; CONVERTING TO FLECAINIDE OR ITS SALT FINE TECH LTD. (IL) 2001-11-13 US claimed
EP-0996616-A1 PROCESS AND A NOVEL INTERMEDIATE FOR THE PREPARATION OF FLECAINIDE Finetech Ltd (IL) 2000-05-03 EP claimed
WO-1999002498-A1 PROCESS AND A NOVEL INTERMEDIATE FOR THE PREPARATION OF FLECAINIDE FINETECH LTD. (IL) 1999-01-21 WO claimed
US-4684733-A Process for the preparation of intermediates of derivatives of pyrrolidine and piperidine RIKER LABORATORIES, INC. (US) 1987-08-04 US claimed
US-4617396-A Process for the preparation of derivatives of piperidine RIKER LABORATORIES, INC. (US) 1986-10-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056794-A1 PROCESS FOR THE PREPARATION OF 2,5-BIS-(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYL-METHYL)-BENZAMIDE AND SALTS THEREOF BOLA2; BOLA2B, TET2, CYP1A2 KDM4E 429/4885ALDH1A1 430/4885CYP2C9 181/4885
US-20020133013-A1 Process for making cyanomethyl ester precursors of flecainide CA2, KCNH1, SCN1B KDM4E 1366/4885ALDH1A1 251/4885CYP2C9 40/4885
US-20100184990-A1 Process for the Manufacture of Flecainide KCND2, KCNH1, KCNH2 KDM4E 478/4885ALDH1A1 960/4885CYP2C9 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.